ImmunoCellular Therapeutics to Leverage BioWa’s Antibody Platform
Potelligent is designed to improve potency and efficacy by enhancing ADCC.!--h2>
BioWa will provide ImmunoCellular Therapeutics with access to its Potelligent® platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. BioWa will receive the right to certain antibody technology from ImmunoCellular Therapeutics and select option rights to antibodies developed using its technology.
Potelligent is designed to improve potency and efficacy of antibody therapeutics by enhancing ADCC, one of the major mechanisms of action for antibody drugs, BioWa explains. The technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a fucosyl transferase-knockout CHO cell line as a production cell. Companies that have licensed Potelligent include Agensys, Daiichi Sankyo, Kalobios, Merck KGaA, and Oxford BioTherapeutics.
ImmunoCellular Therapeutics is developing immunotherapies and mAbs for various cancers. It recently started a Phase II trial with its lead candidate, ICT-107. The compound is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for newly diagnosed glioblastoma.
Another glioblastoma candidate being developed by ImmunoCellular Therapeutics is ICT-121. It is an off-the-shelf, peptide-based vaccine that works by stimulating an immune response to CD-133, a protein that is overexpressed by many CSCs. The molecule is being tested in preclinical studies. Also at the preclinical stage are three mAb therapeutic candidates and one mAb-based diagnostic.